Considerations for Perioperative Opioid Analgesic Stewardship in Australia: A Focus on Tapentadol

References

• Le Merrer J , BeckerJA , BefortK , KiefferBL. Reward processing by the opioid system in the brain. Physiol. Rev.89(4), 1379–1412 (2009).
   PubMed Web of Science ®Google Scholar
• Rosenblum A , MarschLA , JosephH , PortenoyRK. Opioids and the Treatment of Chronic Pain: Controversies, Current Status, and Future Directions. Exp. Clin. Psychopharmacol.16(5), 405–416 (2008).
   PubMed Web of Science ®Google Scholar
• Welfare AIOHA . Opioid harm in Australia and comparisons between Australia and Canada (2018).
   Google Scholar
• Penington Institute . Australia’s Annual Overdose Report 2022 (2022). www.penington.org.au/overdose/overdose-projects-campaigns/australias-annual-overdose-report/
   Google Scholar
• Therapeutic Goods Administration . Opioid reforms: information for sponsors (12/09/2022). www.tga.gov.au/resources/resource/guidance/opioid-reforms-information-sponsors
   Google Scholar
• Medicine AaNZCOaTFOP . Statement on principles for identifying and preventing opioid-induced ventilatory impairment (OIVI): statement on principles for identifying and preventing opioid-induced ventilatory impairment (OIVI) in the acute pain setting.
   Google Scholar
• Care ACOSaQIH . Opioid Analgesic Stewardship in Acute Pain Clinical Care Standard – Acute care edition (2022).
   Google Scholar
• Pain Australia . Impact of 2020 opioid reforms on people living with chronic pain (2020).
   Google Scholar
• Pain Australia . Impact of opioid regulatory reforms on people living with chronic pain (2022).
   Google Scholar
• Langford AV , GnjidicD , LinC-WCet al. Challenges of opioid deprescribing and factors to be considered in the development of opioid deprescribing guidelines: a qualitative analysis. BMJ Qual. Saf.30(2), 133–140 (2021).
   PubMed Web of Science ®Google Scholar
• Langford A , SchneiderC , LinCet al. Evidence-based Clinical Practice Guideline for Deprescribing Opioid Analgesics. The University of Sydney, Sydney (2022).
   Google Scholar
• Hyland SJ , BrockhausKK , VincentWRet al. Perioperative Pain Management and Opioid Stewardship: A Practical Guide. Healthcare9(3), 333 (2021).
   Web of Science ®Google Scholar
• Welfare AIOHA . Elective surgery (2021).
   Google Scholar
• Medicine AaNZCOaTFOP . PS41(G) Position statement on acute pain management 2022 (2022).
   Google Scholar
• Mcanally H . Rationale for and approach to preoperative opioid weaning: a preoperative optimization protocol. Perioperative Med.6(19), 1–10 (2017).
   Google Scholar
• Schug S , PalmerG , ScottD , AlcockM , MottRHJ. APM:SE Working Group of the Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine. Acute Pain Management: Scientific Evidence (5th Ed.). (2020).
   Google Scholar
• Johnston M , VogeleC. Benefits of psychological preparation for surgery: a meta-analysis. Ann. Behav. Med.15(4), 245–256 (1993).
   Google Scholar
• Vasilopoulos T , WardhanR , RashidiPet al. Patient and Procedural Determinants of Postoperative Pain Trajectories. Anesthesiology134, 421–434 (2021).
   PubMed Web of Science ®Google Scholar
• Practitioners TRaCOG . Prescribing drugs of dependence in general practice, Part C2: the role of opioids in pain management.
   Google Scholar
• Seqirus Pty. Ltd . AUSTRALIAN PRODUCT INFORMATION – PALEXIA® IR. (2022).
   Google Scholar
• Raffa RB . On subclasses of opioid analgesics. Curr. Med. Res. Opin.30(12), 2579–2584 (2014).
   PubMed Web of Science ®Google Scholar
• Pergolizzi JVJ , LequangJA , TaylorRJ , OssipovMH , ColucciD , RaffaRB. Designing safer analgesics: a focus on μ-opioid receptor pathways. Expert Opin. Drug Discov.13(10), 965–972 (2018).
   PubMed Web of Science ®Google Scholar
• Raffa RB , EllingC , TzschentkeTM. Does ‘Strong Analgesic’ Equal ‘Strong Opioid’? Tapentadol and the Concept of ‘μ-Load’. Adv. Ther.35(10), 1471–1484 (2018).
   PubMed Web of Science ®Google Scholar
• Wang X , NarayanSW , PenmJ , PatanwalaAE. Efficacy and Safety of Tapentadol Immediate Release for Acute Pain A Systematic Review and Meta-Analysis. Clin. J. Pain36(5), 399–409 (2020).
   PubMed Web of Science ®Google Scholar
• Xiao J-P , LiA-L , FengB-M , YeY , WangG-J. Efficacy and Safety of Tapentadol Immediate Release Assessment in Treatment of Moderate to Severe Pain: A Systematic Review and Meta-Analysis. Pain Medicine18(1), 14–24 (2017).
   PubMed Web of Science ®Google Scholar
• Hartrick C , HoveIV , StegmannJ-U , OhC , UpmalisD. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: A 10-day, phase III, randomized, double-blind, active- and placebo-controlled study. Clin. Ther.31(2), 260–271 (2009).
   PubMed Web of Science ®Google Scholar
• FPM ANZCA . Faculty of Pain Medicine of the Australian and New Zealand College of Anaesthetists Opioid Calculator. (2.9.1). (2020).
   Google Scholar
• Wang X , PenmJ , PatanwalaAE. Cost-effectiveness of tapentadol immediate release versus oxycodone immediate release for acute post-operative pain after major hip surgeries. Curr. Med. Res. Opin.38(1), 399–409 (2022).
   Web of Science ®Google Scholar
• Ruggeri M , SignoriniA , CaravaggioS , SantoriC , RosielloF , ColuzziF. Cost-Effectiveness Analysis of Tapentadol Versus Oxycodone/Naloxone in both Branded and Generic Formulations in Patients with Musculoskeletal Pain. Clin. Drug Investig41(10), 875–883 (2021).
   PubMed Web of Science ®Google Scholar
• Kwong WJ , Ozer-StillmanI , MillerJD , HaberNA , RussellMW , KavanaghS. Cost-effectiveness analysis of tapentadol immediate release for the treatment of acute pain. Clin. Ther.32(10), 1768–1781 (2010).
   PubMed Web of Science ®Google Scholar
• Paris A , KozmaCM , ChowW , PatelAM , ModySH , KimMS. Modeling the Frequency and Costs Associated with Postsurgical Gastrointestinal Adverse Events for Tapentadol IR versus Oxycodone IR. American Health & Drug Benefits6(9), 567–575 (2013).
   PubMedGoogle Scholar
• Coluzzi F , RuggeriM. Clinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain. Curr. Med. Res. Opin.30(6), 1139–1151 (2014).
   PubMed Web of Science ®Google Scholar
• Obradovic M , IkenbergR , HertelN , AntoñanzasF , GálvezR , LiedgensH. Cost-effectiveness of tapentadol in severe chronic pain in Spain: a cost analysis of data from RCTs. Clin. Ther.34(4), 926–943 (2012).
   PubMed Web of Science ®Google Scholar
• Yiu CH , GnjidicD , PatanwalaAet al. Opioid-related adverse drug events in surgical patients: risk factors and association with clinical outcomes. Expert Opin. Drug Saf.27, 1–13 (2022).
   Google Scholar
• Yiu CH , VitharanaN , GnjidicDet al. Patient risk factors for opioid-related adverse drug events in hospitalized patients: a systematic review. Pharmacotherapy42(3), 194–215 (2022).
   PubMed Web of Science ®Google Scholar
• Suh D-C , KimMS , ChowW , JangE-J. Use of Medications and Resources for Treatment of Nausea, Vomiting, or Constipation in Hospitalized Patients Treated With Analgesics. Clin. J. Pain27(6), 508–517 (2011).
   PubMed Web of Science ®Google Scholar
• Oderda GM , EvansRS , LloydJet al. Cost of opioid-related adverse drug events in surgical patients. J. Pain Symptom Manage.25(3), 276–283 (2003).
   PubMed Web of Science ®Google Scholar
• Candrilli SD , DavisKL , IyerS. Impact of constipation on opioid use patterns, health care resource utilization, and costs in cancer patients on opioid therapy. J. Pain Palliat. Care Pharmacother.23(3), 231–241 (2009).
   PubMedGoogle Scholar
• Lin J , ChowW , KimMS , RupnowMFT. Real-world treatment pattern and outcomes among patients who took tapentadol IR or oxycodone IR. J. Med. Econ.16(5), 685–690 (2013).
   PubMedGoogle Scholar
• Mark EB , NedergaardRB , HansenTMet al. Tapentadol results in less deterioration of gastrointestinal function and symptoms than standard opioid therapy in healthy male volunteers. Neurogastroenterol. Motil.33(11), 1–10 (2021).
   Web of Science ®Google Scholar
• Webster L , RauckRL. Atypical opioids and their effect on respiratory drive. J. Opioid Management17(7), 109–118 (2021).
   PubMedGoogle Scholar
• Schrier RVD , JonkmanK , VelzenMVet al. An experimental study comparing the respiratory effects of tapentadol and oxycodone in healthy volunteers. Br. J. Anaesth.119(6), 1169–1177 (2017).
   PubMed Web of Science ®Google Scholar
• Limited TG . eTG complete, Pain and Analgesia [digital]. (2020).
   Google Scholar
• Schug SA , PalmerGM , ScottDA , HalliwellR , TrincaJ. APM:SE Working Group of the Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine. Acute Pain Management: Scientific Evidence (5th Ed.). (2020).
   Google Scholar
• Afilalo M , EtropolskiM , KuperwasserBet al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin. Drug Investig.30(8), 489–505 (2010).
   PubMed Web of Science ®Google Scholar
• Buynak R , ShapiroD , OkamotoAet al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled phase III study. Expert Opin. Pharmacotherapy11(11), 1787–1804 (2010).
   PubMed Web of Science ®Google Scholar
• Wild J , GrondS , KuperwasserBet al. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract.10(5), 416–427 (2010).
   PubMed Web of Science ®Google Scholar
• Buynak R , RappaportSA , RodKet al. Long-term safety and efficacy of tapentadol extended release following up to 2 years of treatment in patients with moderate to severe, chronic pain: results of an open-label extension trial. Clin. Ther.37(11), 2420–2438 (2015).
   PubMed Web of Science ®Google Scholar
• Águila MJSD , SchenkM , KernK-U , DrostT , SteigerwaldI. Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain. Clin. Ther.37(1), 94–113 (2015).
   PubMed Web of Science ®Google Scholar
• Ashworth J , LangeB , LangeR , EtA. Pooled analysis of opioid withdrawal outcomes in phase 2/3 trials of tapentadol prolonged release. Poster presented at: the Annual Scientific Meeting of the British Pain Society (BPS); April 13-16, 2010; Manchester, UK (2010).
   Google Scholar
• Lam T , BiggsN , XiaTet al. Comparing opioid types in the persistence of opioid use following surgical admission: a study protocol for a retrospective observational linkage study comparing tapentadol and oxycodone in Australia. BMJ Open12(4), e060151 (2022).
   PubMed Web of Science ®Google Scholar
• Lam T , XiaT , BiggsNet al. Effect of discharge opioid on persistent postoperative opioid use: a retrospective cohort study comparing tapentadol with oxycodone. Anaesthesia78(4), 420–431 (2022).
   PubMed Web of Science ®Google Scholar